ArticleDocumenta ophthalmologica. Advances in ophthalmology2026
Evaluation of optic nerve and retinal functions in demyelinating diseases using electrophysiological tests.
Article in Documenta ophthalmologica. Advances in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to evaluate pattern visual evoked potential (PVEP) and pattern electroretinography (PERG) parameters during the attack-free period in patients with multiple sclerosis (MS) with and without a history of optic neuritis (ON), as well as in individuals with non-MS demyelinating diseases and healthy controls. MATERIALS AND
methodsThis cross-sectional study included 71 patients with demyelinating diseases (95 eyes) and 44 healthy volunteers (88 eyes). This study was prospectively designed to evaluate clinical and electrophysiological data obtained during the routine diagnostic work-up and follow-up in our Neuro-ophthalmology Unit. Patients were classified into three groups: MS with ON (MS + ON), MS without ON (MS-ON), and non-MS demyelinating disorders with ON (non-MS + ON). All participants underwent a comprehensive ophthalmological examination followed by PVEP and PERG testing. Tests were conducted using the Metrovision Monpack system. The peak latencies and amplitudes of the PVEP N75 and P100 waves, as well as the peak latencies and amplitudes of the PERG P50 and N95 waves, were analyzed and compared with control subjects. To account for inter-eye dependency, we employed Generalized Estimating Equations (GEE), specifying a Gaussian family with an identity link function and an exchangeable working correlation structure. Results are reported as median (range) and Mean Differences (MD) with 95% CI.
resultsIn the MS + ON group, a significant prolongation of P100 latency along with marked reductions in both P100 and N95 amplitudes was observed (p < 0.001), indicating demyelination accompanied by axonal damage. Additionally, the MS - ON group demonstrated a significant prolongation of P100 latency (p = 0.02) and a reduction in N95 amplitude (p = 0.005), suggestive of subclinical retinal ganglion cell dysfunction in the absence of ON. In the non-MS + ON group, although P100 latency was prolonged (p = 0.01), P100 amplitude was preserved (p = 0.28); however, a significant reduction in N95 amplitude was detected (p = 0.002). Effect sizes were expressed as Mean Differences (MD) with 95% Confidence Intervals (CI) to emphasize clinical magnitude over binary p-values.
conclusionIn combination with PVEP, PERG enhances neuro-ophthalmological evaluation by revealing optic nerve and retinal ganglion cell involvement across both acute and chronic stages of demyelinating diseases.
Indexed as
Identifiers
42414766What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.